Latest News - Biogen
Top Corporates Hub
Biogen
Can Corcept Therapeutics Stock Rally 40% After This Dip?
26.10.2026 07:11
For questions about this article or underlying research, email help@trefis.com.
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
22.10.2026 13:00
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244
22.10.2026 07:38
B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $219 to $244.
RBC Capital names top healthcare stocks as sector upgraded to overweight
20.10.2026 19:27
Investing.com -- RBC Capital has upgraded the Healthcare sector to Overweight from Market Weight, identifying 11 high-conviction stock ideas across therapeutics and non-therapeutics segments. The upgrade is supported by improving flows, positive earnings and sales revision profiles, and attractive valuations. RBC Head of Equity Strategy Lori Calvasina noted that Healthcare historically moves inversely to Technology’s relative performance versus the S&P 500, making it a natural destination when r
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
20.10.2026 13:30
BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.
Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310
20.10.2026 09:55
Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $250 to $310.
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
19.10.2026 12:00
ABBV's neuroscience franchise targets nearly 16% revenue growth in Q3, with established drugs and newer Parkinson's therapies driving expansion.
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
19.10.2026 11:30
Two oral presentations to highlight new 76-week data showing sustained proteinuria reduction and continued eGFR stabilization with a consistent long-term safety profileAdditional presentations to highlight nephrologist perspectives on gaps in current care practices and limited treatment options for antibody-mediated rejection (AMR)Presentations on the role of felzartamab, an investigational anti-CD38 monoclonal antibody, in multiple immune-mediated kidney diseases will also be featured CAMBRIDGE
Biogen To Demonstrate Data, Additional Scientific Presentations From Its Nephrology Portfolio At American Society Of Nephrology Kidney Week
19.10.2026 07:32
Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the American Society of
A kidney transplant milestone has Wall Street excited about Biogen
17.10.2026 00:37
JPMorgan strongly reset its price target on the company’s attractive 2027 pipeline catalysts.
Biogen-backed Estuary nabs $93M for kidney disease gene therapy
16.10.2026 10:30
The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
16.10.2026 08:28
Biogen's Q3 earnings are due Oct 28. Explore FY2026 EPS guidance, Alzheimerâs revenue growth, and key risk/reward driversâread now. Click for this BIIB update.
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027
04.10.2026 10:08
Design Therapeutics initiated at Hold: DT-216P2 shows early FA RESTORE-FA gains; watch Q4 '26/Q1 '27 catalysts and cash runway. Click for more on DSGN stock.
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
02.10.2026 15:20
Continued improvement: An increased response was seen in participants on litifilimab from week 24 through week 52, with more individuals achieving clear or almost clear skin (27.2%; CLA IGA 0-1) and improvements in disease activity (28.8%; CLASI-70) than at week 24 (19.0% and 21.7%, respectively)Rapid onset: Participants that switched from placebo to litifilimab experienced improvements in skin disease activity in as early as four weeks -- consistent with results seen in participants who started
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
02.10.2026 13:00
AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.
1 Profitable Stock Worth Investigating and 2 We Ignore
01.10.2026 11:41
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
1 Profitable Stock Worth Investigating and 2 We Ignore
01.10.2026 11:41
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
HLS Therapeutics Announces Board of Directors Changes
01.10.2026 11:00
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Directors (the "Board"), effective today. The appointments follow the departures of Dr. Kyle Dempsey and Christine Elliott. Following these changes, the Board comprises eight directors, six of whom are independent.
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
29.09.2026 04:23
Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.
Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued?
23.09.2026 09:15
Biogen (BIIB) is back in focus after publishing adolescent subgroup data from its Phase 3 VALIANT trial of EMPAVELI in rare kidney diseases, a catalyst that gives investors fresh clinical context around the stock. For context, Biogen’s recent clinical and product news has landed against a backdrop of stronger trading action, with a 1-day share price return of 2.87% on the latest close at US$225.36 and a 90-day share price return of 12.91%. Investors are weighing kidney and Alzheimer’s updates...